Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis

Pearce, Alison; Ryan, Fay; Drummond, Frances J.; Thomas, Audrey Alforque; Timmons, Aileen; Sharp, Linda

doi:10.1007/s00520-015-2857-8

Cited by 6 publications

(4 citation statements)

References 19 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other side, Pearce and colleagues stated that postoperative pain management is crucial for procedure-related cost minimization. 11 In the present study, we achieved significantly lower VAS score at first hour, sixth hour and 24 th hour following RFA.…”

Section: Discussionsupporting

confidence: 55%

Comparison of Radiofrequency Ablation and Saphenous Vein Stripping for the Treatment of Recurrent Lower Extremity Venous Insufficiency

Kanber

Cetin

2023

Vasc Endovascular Surg

View full text Add to dashboard Cite

Objective To compare the efficiency and safety of radiofrequency ablation (RFA) and saphenous vein stripping (SVS) for the treatment of recurrent lower extremity chronic superficial venous insufficiency (CSVI). Methods Patients who underwent SVS and RFA for recurrent lower extremity CSVI following RFA and patients who had 2-year follow-up results were enrolled into the study. Total, 37 patients who underwent a second RFA session with 2-year follow-up results were available. Then 37 patients were selected from 88 patients who underwent SVS for recurrent lower extremity CSVI to achieve a 1:1 ratio for comparison. Groups were compared based on preoperative properties, operative parameters, postoperative outcomes, complications and follow-up results. Results Duration of the procedure was 20.7 minutes in the RFA group and 30.7 minutes in the SVS group (P = .001). Postoperative pain at first hour, sixth hour and 24th hour were significantly lower in patients who underwent RF (P = .001 for each parameter). Moreover, hospitalization time (18.1 hours vs 24.6 hours, P = .001) and time to return to normal daily activities (1.6 days and 2.5 days, P = .001) were significantly shorter in the RFA group. Success of the procedure did not statistically significant at first year follow-up (P = .304). However, success was significantly higher for the SVS group at second year follow-up (73% for RFA group and 91.9% for SVS group, P = .032). Conclusion We achieved significantly shorter procedure time, less postoperative hospitalization time, and a shorter time to return to daily activities with RFA. In contrast, the success rate of SVS was significantly higher at the second year follow-up, but not the first year follow-up in comparison with RFA.

show abstract

Section: Discussionsupporting

confidence: 55%

Comparison of Radiofrequency Ablation and Saphenous Vein Stripping for the Treatment of Recurrent Lower Extremity Venous Insufficiency

Kanber

Cetin

2023

Vasc Endovascular Surg

View full text Add to dashboard Cite

show abstract

“…The authors concluded that HAL BLFC allowed more outpatient treatment, improved recurrence detection, reduced transurethral resection of bladder tumors and reduced cystectomies, bed days and operating room time with minimal cost impact across all risk groups. A Markov model was built to investigate the cost of three different follow-up strategies for prostate cancer patients treated with curative intent in the Irish setting [ 49 ]. Pearce et al [ 49 ] conducted a cost minimization analysis, and the results were supported by a one-way sensitivity analysis and PSA.…”

Section: Resultsmentioning

confidence: 99%

“…A Markov model was built to investigate the cost of three different follow-up strategies for prostate cancer patients treated with curative intent in the Irish setting [ 49 ]. Pearce et al [ 49 ] conducted a cost minimization analysis, and the results were supported by a one-way sensitivity analysis and PSA. They found that the current Irish practice was the least cost-efficient option for prostate cancer follow-up care, while the implementation of alternative models of care such as the NICE guidelines would lead to significant cost savings in the Irish healthcare system.…”

Section: Resultsmentioning

confidence: 99%

Economic Evaluation of Long-Term Survivorship Care for Cancer Patients in OECD Countries: A Systematic Review for Decision-Makers

Jadambaa

2021

IJERPH

View full text Add to dashboard Cite

Long-term cancer survivorship care is a crucial component of an efficient healthcare system. For numerous reasons, there has been an increase in the number of cancer survivors; therefore, healthcare decision-makers are tasked with balancing a finite budget with a strong demand for services. Decision-makers require clear and pragmatic interpretation of results to inform resource allocation decisions. For these reasons, the impact and importance of economic evidence are increasing. The aim of the current study was to conduct a systematic review of economic evaluations of long-term cancer survivorship care in Organization for Economic Co-operation and Development (OECD) member countries and to assess the usefulness of economic evidence for decision-makers. A systematic review of electronic databases, including MEDLINE, PubMed, PsycINFO and others, was conducted. The reporting quality of the included studies was appraised using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Each included study’s usefulness for decision-makers was assessed using an adapted version of a previously published approach. Overall, 3597 studies were screened, and of the 235 studies assessed for eligibility, 34 satisfied the pre-determined inclusion criteria. We found that the majority of the included studies had limited value for informing healthcare decision-making and conclude that this represents an ongoing issue in the field. We recommend that authors explicitly include a policy statement as part of their presentation of results.

show abstract

“…Precisely, the measurement of PSA for follow-ups has been controversially discussed as it was found to decrease mortality from prostate cancer but does not alter all-cause mortality [11][12][13]. Pearce et al (2016) previously evaluated the cost of follow-up strategies across the UK [14]. He concluded that Ireland could have saved up to 26% of follow-up costs per year by implementing the European Association of Urology's (EAU) or National Institute for Health and Care Excellence's (NICE) guidelines.…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer follow-up costs in Germany from 2000 to 2015

Michaeli

2021

J Cancer Surviv

View full text Add to dashboard Cite

Purpose The main objective of this study is to estimate and evaluate 10-year follow-up costs after prostate cancer treatment with curative (surgery, radiotherapy) and non-curative intent (hormone, androgen deprivation) per patient in Germany in 2000, 2008, and 2015. Methods Prostate cancer follow-up recommendations were extracted from the European Association of Urology guidelines from 2000 to 2015. Per patient costs were calculated with a detailed micro-costing approach considering direct and indirect medical expenses. Input parameters were derived from expert interviews, literature research, and official scales of tariffs. Costs for insurers, providers, and payers were included to estimate societal costs. Results Mean 10-year follow-up costs per patient after treatment with curative intent amounted to EUR 4415 in 2000, EUR 4224 in 2008 (p < 0.001), and EUR 5159 in 2015 (p < 0.001). Costs after hormone therapy with metastasis cumulated to EUR 10,846 in 2000, EUR 9818 in 2008 (p < 0.001), and EUR 11,978 in 2015 (p < 0.001). While insurers covered 37% of costs in 2000 (EUR 1664), only 23% of costs were reimbursed in 2015 (EUR 1195; p < 0.001). Cost sources mainly included consultations (55%), transportation (18%), and imaging (27%). Conclusion Early detection and advances in prostate cancer treatment increased 10-year survival rates beyond 80% in Germany, ultimately expanding the number of survivors requiring follow-up. Statutory insurers reacted by decreasing the reimbursement rates to reduce per patient cost by up to 46%. Consequently, the economic burden was mainly shifted to payers and providers. Implications for Cancer Survivors Equitable and effective follow-up schedules covered by insurance funds are necessary to care for prostate cancer patients.

show abstract

Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis

Cited by 6 publications

References 19 publications

Comparison of Radiofrequency Ablation and Saphenous Vein Stripping for the Treatment of Recurrent Lower Extremity Venous Insufficiency

Comparison of Radiofrequency Ablation and Saphenous Vein Stripping for the Treatment of Recurrent Lower Extremity Venous Insufficiency

Economic Evaluation of Long-Term Survivorship Care for Cancer Patients in OECD Countries: A Systematic Review for Decision-Makers

Prostate cancer follow-up costs in Germany from 2000 to 2015

Contact Info

Product

Resources

About